Scrip Intelligence launches Scrip 100 2012
This article was originally published in Scrip
Executive Summary
Scrip Intelligence has launched the latest Scrip 100, its annual look at the performance and prospects of the global pharmaceutical industry over the past year.
You may also be interested in...
Hoops, hoopla, big ideas and diabetes
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
How Dennis Gillings took a gamble and built a $3.7bn business
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"